Previous Close | 4.95 |
Open | 5.24 |
Bid | 5.01 x 800 |
Ask | 7.91 x 900 |
Day's Range | 5.20 - 5.24 |
52 Week Range | 4.29 - 7.08 |
Volume | |
Avg. Volume | 1,952 |
Market Cap | 95.457M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.78 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for GNTA
Key Insights Significant control over Genenta Science by individual investors implies that the general public has more...
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences. H.C. Wainwright 25th Annual Global Investment Conference, September 11-13 2023, NYC-USPresenters: Pierluigi Paracchi, CEO and Co-founder, Carlo Russo, CMO
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second IndicationCompany Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors